Antibiotic resistant bacteria, particularly in chronic infections, are difficult and costly to treat, so research into detection, identification, and treatment options is critical. Susceptibility measurement must accurately reflect the degree to which the strain will respond to antibiotics, so the first investigation was of parameters that affect antimicrobial susceptibility testing such as agar depth and hydration. Additionally, in order to study new ways in which bacteria may be vulnerable to antimicrobials, researchers must experimentally evolve bacteria to be drug-resistant. The second methodological investigation involved development of an easy, cost- and labor-efficient process for laboratory evolution of antibiotic-resistant bacteria.Burkholderia multivorans, a member of the Burkholderia cepacia complex (Bcc), can cause chronic lung infections in vulnerable patients. A possible treatment for chronic infections arises from the existence of collateral sensitivity (CS): decreased resistance to a non-treatment antibiotic acquired along with resistance to the treatment drug. Identifying CS patterns for bacteria may lead to sustainable treatment regimens that reduce development of multidrug resistant bacterial strains. CS has been found to occur in E. coli, P. aeruginosa, and S. aureus. The two latter studies report that B. multivorans exhibits antibiotic CS, as well as cross resistance (CR), describe CS and CR networks for six clinically-relevant antibiotics, and identify reciprocal CS drug pairs. Characterization of CS and CR patterns allow antibiotics to be separated into two clusters, which is a first step towards predicting antibiotic therapy strategies.